Torrent Pharmaceuticals Limited
TORNTPHARM
Clasificación en acciones
#1200
Torrent Pharmaceuticals Limited operates as a global pharmaceutical entity,... Torrent Pharmaceuticals Limited operates as a global pharmaceutical entity, managing the entire process from the discovery and development of generic drug formulations to their production and distribution. Its commercial activities extend across key markets such as India, the United States, Germany, and Brazil, alongside various other international territories. The company boasts a broad product catalog, offering treatments for a wide array of medical conditions. This includes therapies for cardiovascular diseases, central nervous system disorders, gastrointestinal issues, women's health concerns, diabetes, pain management, gynecological ailments, oncology, and anti-infective medications. Additionally, Torrent Pharma supplies essential vitamins, minerals, and other nutritional supplements. Beyond its proprietary offerings, the firm also provides contract manufacturing services to other companies. During the COVID-19 pandemic, it demonstrated its commitment by securing licensing agreements for crucial treatments like Baricitinib, Molnupiravir, and Paxlovid. Established in 1959, the company originally operated under the name Trinity Laboratories before officially becoming Torrent Pharmaceuticals Limited in 1971. Its corporate headquarters are located in Ahmedabad, India. Ultimately, Torrent Pharmaceuticals Limited functions as a subsidiary of Torrent Investments Private Limited.
Precio por acción
$50.31
Última sincronización: 2026-10-19
Capitalización bursátil
$19.14B
Cambio (1 día)
-0.14%
Cambio (1 año)
23.32%
País
IN
Comercio Torrent Pharmaceuticals Limited (TORNTPHARM)
Categoría
Healthcare
Ratio P/E de Torrent Pharmaceuticals Limited (TORNTPHARM)
Ratio P/E al October 2026 TTM: 71.64
Según los últimos informes financieros y el precio de las acciones de Torrent Pharmaceuticals Limited, el P/E actual (TTM) de la empresa es 71.64. Al final de 2024, la empresa tenía un P/E de 54.66.
Historial del ratio P/E de Torrent Pharmaceuticals Limited desde 2005 hasta 2026
Relación P/E al final de cada año
| Año | Ratio P/E | Cambiar |
|---|---|---|
| 2026 (TTM) | 71.64 | 27.07% |
| 2025 | 56.38 | 3.14% |
| 2024 | 54.66 | 30.84% |
| 2023 | 41.78 | -31.28% |
| 2022 | 60.79 | 76.71% |
| 2021 | 34.40 | 5.65% |
| 2020 | 32.56 | -55.81% |
| 2019 | 73.70 | 133.20% |
| 2018 | 31.60 | 12.29% |
| 2017 | 28.14 | 113.73% |
| 2016 | 13.17 | -49.56% |
| 2015 | 26.11 | 95.38% |
| 2014 | 13.36 | 0.29% |
| 2013 | 13.32 | -29.07% |
| 2012 | 18.78 | 3.34% |
| 2011 | 18.18 | -8.93% |
| 2010 | 19.96 | 224.61% |
| 2009 | 6.15 | -30.48% |
| 2008 | 8.85 | -50.07% |
| 2007 | 17.72 | -50.96% |
| 2006 | 36.12 | 88.10% |
| 2005 | 19.21 | 0.00% |
Relación P/E para empresas similares o competidores
| Empresa | P/E Ratio | Diferencia del P/E Ratio | País |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 34.96 | -51.20% |
IN
|
¿Cómo leer un P/E ratio?
El ratio Precio/Beneficio (P/E Ratio) mide la relación entre el precio de las acciones de una empresa y sus beneficios por acción.
Un P/E bajo pero positivo indica una empresa con altos beneficios en relación a su valoración actual y que podría estar infravalorada. Una empresa con un P/E negativo alto (cerca de 0) indica fuertes pérdidas en comparación con su valoración.
Las empresas con un P/E superior a 30 o negativo suelen considerarse "acciones de crecimiento", lo que significa que los inversores esperan que crezca o se vuelva rentable en el futuro.
Las empresas con un P/E positivo inferior a 10 suelen considerarse "acciones de valor", lo que significa que ya son muy rentables y no se espera un fuerte crecimiento.